Komori
Revision to earnings forecast4538Fuso Pharmaceutical Industries,Ltd.Pharmaceuticals

Notice Regarding Revisions to Earnings Forecasts and Year-End Dividend Forecast (Increase)

The full-year forecast for the fiscal year ending March 2027 has been revised upward, with sales raised by ¥1,600 million, operating profit by ¥400 million, ordinary profit by ¥400 million and net income by ¥200 million. The forecast for the year-end dividend has also been increased from ¥45 to ¥46 per share, and the forecast for the annual dividend from ¥90 to ¥91.

Worth reading
66In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
20
% (percentage change in operating income)
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending March 2027 · Full yearPrevious forecast published 12 May 2026
Net Sales63,200→64,800million
+2.5%
Operating profit2,000→2,400million
+20.0%
Ordinary income1,400→1,800million
+28.6%
Profit attributable to owners of the parent1,300→1,500million
+15.4%
Net income per share152.25→175.73Yen / sen
+15.4%

The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.

Reason for the revision

Sales trends, which remained firm in the first half, are expected to continue in the second half. Although the impact of higher prices for related raw materials and other inputs against the backdrop of the situation in the Middle East is expected to emerge in the second half, and research and development expenses are expected to increase as research and development progresses, profits are expected to exceed the previous forecast based on first-half results.

Previous-period resultsSales ¥62,307 million, operating profit ¥2,639 million, ordinary profit ¥2,349 million, net income ¥2,011 million, net income per share ¥235.63 (fiscal year ended March 2026)
Dividend forecast revisionThe forecast for the year-end dividend was increased from ¥45 to ¥46 per share, and the forecast for the annual dividend was increased from ¥90 to ¥91.
Revised forecast
ItemDetails
Net Sales¥63,200 million → ¥64,800 million(+2.5%)
Operating profit¥2,000 million → ¥2,400 million(+20.0%)
Ordinary income¥1,400 million → ¥1,800 million(+28.6%)
Profit attributable to owners of the parent¥1,300 million → ¥1,500 million(+15.4%)
Net income per share152.25 Yen / sen → 175.73 Yen / sen
Fiscal Period CoveredFiscal year ending March 2027
Period CoveredFull year
Publication date of previous forecast12 May 2026
Previous-period resultsSales ¥62,307 million, operating profit ¥2,639 million, ordinary profit ¥2,349 million, net income ¥2,011 million, net income per share ¥235.63 (fiscal year ended March 2026)
Reason for the revisionSales trends, which remained firm in the first half, are expected to continue in the second half. Although the impact of higher prices for related raw materials and other inputs against the backdrop of the situation in the Middle East is expected to emerge in the second half, and research and development expenses are expected to increase as research and development progresses, profits are expected to exceed the previous forecast based on first-half results.
Dividend forecast revisionThe forecast for the year-end dividend was increased from ¥45 to ¥46 per share, and the forecast for the annual dividend was increased from ¥90 to ¥91.
Items this document does not state (2)
Details and amount of extraordinary lossConsolidated / non-consolidated

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Sales were revised upward because sales trends were firm in the first half and are expected to remain so in the second half. Although raw material and other related input prices are expected to rise against the backdrop of the situation in the Middle East, and research and development expenses are expected to increase, operating profit, ordinary profit and net income were revised upward based on first-half results. The dividend was increased after considering the profit distribution policy, recent earnings trends, the balance between maintaining a stable supply structure, investment in growth areas and shareholder returns.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Revisions to Earnings Forecasts and Year-End Dividend Forecast (Increase) | Fuso Pharmaceutical Industries,Ltd. (4538) timely disclosure | Komori